Meeting
2017 Gastrointestinal Cancers Symposium
Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome.
Authors
Stacie Hudgens
Clinical Outcomes Solutions, Tucson, AZ
Stacie Hudgens , Jonathon Gable , Matthew H. Kulke , Emily Bergsland , Lowell Brian Anthony , Martyn E. Caplin , Kjell E. Oberg , Marianne E. Pavel , Phillip Banks , Qi Melissa Yang , Pablo Lapuerta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 583)
DOI
10.1200/JCO.2017.35.4_suppl.583
Abstract #
583
Poster Bd #
D1
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Exploring telotristat ethyl’s antiproliferative effects in patients with carcinoid syndrome (TELEACE): A real-world observational study.
First Author: Michael Morse
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized, parallel arm, phase II study of telotristat (Xermelo) in combination with lutetium Lu 177 dotatate (Lutathera) in well-differentiated neuroendocrine tumors (NETs).
First Author: Aman Chauhan
Poster
2021 Gastrointestinal Cancers Symposium
Cost of treatment change among patients with neuroendocrine tumors (NET) treated originally with somatostatin analogs.
First Author: Bernard Tawfik
Poster
2018 Gastrointestinal Cancers Symposium
Time to sustained improvement in bowel movement frequency with telotristat ethyl: Analysis of the phase III telecast study.
First Author: Joseph Dillon